✓ In order to determine the in vivo immune response in glioblastoma, monoclonal and polyclonal antibodies specific for inflammatory leukocytes and immunoregulatory products were utilized to stain tissue from four surgical specimens. The more activated the inflammatory cells, the more activated the tumors appeared to be. In the tumor with the largest infiltration (Case 3), inflammatory cells were stained for interferon-γ interleukin-2. interleukin-1β. lymphotoxin, tumor necrosis factor-µ, and transforming growth factor-β. The tumor cells also expressed interleukin-1β, interleukin-6, transforming growth factor-β, tumor necrosis factor-µ, and prostaglandin E. In contrast, in the tumor with the least inflammatory response (Case 1), the tumor cells did not express any cytokines. Expression of cytokines by glioma cells was modest in the two cases with modest inflammatory responses. Cellular inflammation, primarily consisting of T cells and macrophages with few or no B cells or natural killer cells, was two- to 15-fold greater outside the tumor than within. In contrast to leukocytes outside the tumor, which were activated and expressing class II major histocompatibility antigens, leukocytes within the tumor parenchyma or at the tumor's edge were negative for these antigens. In the four specimens studied here, the tumor cells themselves were also negative for class II major histocompatibility antigens. These findings, although preliminary, suggest that inflammatory cells within gliomas are inactivated and that glioma cells may increase the expression of immunosuppressive cytokines in response to an increased lymphocyte infiltrate. This observation, if corroborated by more extensive studies, may help to explain the failure of immune treatments in glioblastoma multiforme.
Barba D, , Saris SC, & Holder C, et al: Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 70:175–182, 1989 Barba D, Saris SC, Holder C, et al: Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 70:175–182, 1989
Benacerraf B: Role of MHC gene products in immune regulation. Science 212:1229–1238, 1981 Benacerraf B: Role of MHC gene products in immune regulation. Science 212:1229–1238, 1981
Bertrand I, & Mannen H: [Study of vascular reactions in astrocytomas.] Rev Neurol 102:3–19, 1960 (Fr) Bertrand 1, Mannen H: [Study of vascular reactions in astrocytomas.] Rev Neurol 102:3–19, 1960 (Fr)
Bodmer S, , Strommer K, & Frei K, et al: Immunosuppression and transforming growth factor-β in glioblastoma. Preferential production of transforming growth factor-β2. Immunol 143:3222–3229, 1989 Bodmer S, Strommer K, Frei K, et al: Immunosuppression and transforming growth factor-β in glioblastoma. Preferential production of transforming growth factor-β2. Immunol 143:3222–3229, 1989
Bonnin JM, & Rubinstein LJ: Immunohistochemistry of central nervous system tumors. Its contribution to neurosurgical diagnosis. J Neurosurg 60:1121–1133, 1984 Bonnin JM, Rubinstein LJ: Immunohistochemistry of central nervous system tumors. Its contribution to neurosurgical diagnosis. J Neurosurg 60:1121–1133, 1984
Chantry D, , Turner M, & Abney E, et al: Modulation of cytokine production by transforming growth factor-β. J Immunol 142:4295–4300, 1989 Chantry D, Turner M, Abney E, et al: Modulation of cytokine production by transforming growth factor-β. J Immunol 142:4295–4300, 1989
Clark WC, & Bressler J: Transforming growth factor-β-like activity in tumors of the central nervous system. J Neurosurg 68:920–924, 1988 Clark WC, Bressler J: Transforming growth factor-β-like activity in tumors of the central nervous system. J Neurosurg 68:920–924, 1988
De Armond SJ, , Eng LF, & Rubinstein LJ: The application of glial fibrillary acidic (GFA) protein immunohistochemistry in neurooncology. A progress report. Pathol Res Pract 168:374–394, 1980 De Armond SJ, Eng LF, Rubinstein LJ: The application of glial fibrillary acidic (GFA) protein immunohistochemistry in neurooncology. A progress report. Pathol Res Pract 168:374–394, 1980
Deck JHN, , Eng LF, & Bigbee J, et al: The role of glial fibrillary acidic protein in the diagnosis of central nervous system tumors. Acta Neuropathol 42:183–190, 1978 Deck JHN, Eng LF, Bigbee J, et al: The role of glial fibrillary acidic protein in the diagnosis of central nervous system tumors. Acta Neuropathol 42:183–190, 1978
Di Lorenzo N, , Palma L, & Nicole S: Lymphocytic infiltration in long-survival glioblastomas: possible host's resistance. Acta Neurochir 39:27–33, 1977 Di Lorenzo N, Palma L, Nicole S: Lymphocytic infiltration in long-survival glioblastomas: possible host's resistance. Acta Neurochir 39:27–33, 1977
Duffy PE, , Huang YY, & Rapport MM, et al: Glial fibrillary acidic protein in giant cell tumors of brain and other gliomas. A possible relationship to malignancy, differentiation, and pleomorphism of glia. Acta Neuropathol 52:51–57, 1980 Duffy PE, Huang YY, Rapport MM, et al: Glial fibrillary acidic protein in giant cell tumors of brain and other gliomas. A possible relationship to malignancy, differentiation, and pleomorphism of glia. Acta Neuropathol 52:51–57, 1980
Eng LF, & Rubinstein LJ: Contribution of immunohistochemistry to diagnostic problems of human cerebral tumors. J Histochem Cytochem 26:513–522 1978 Eng LF, Rubinstein LJ: Contribution of immunohistochemistry to diagnostic problems of human cerebral tumors. J Histochem Cytochem 26:513–522 1978
Espevik T, , Figari IS, & Ranges GE, et al: Transforming growth factor-β1 (TGF-β1) and recombinant human tumor necrosis factor-α reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-β1 and TGF-β1, and recombinant human TGF-β1. J Immunol 140:2312–2316, 1988 Espevik T, Figari IS, Ranges GE, et al: Transforming growth factor-β1 (TGF-β1) and recombinant human tumor necrosis factor-α reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-β1 and TGF-β1, and recombinant human TGF-β1. J Immunol 140:2312–2316, 1988
Fierz W, , Endler B, & Reske K, et al: Astrocytes as antigen-presenting cells. 1. Induction of la antigen expression on astrocytes by T cells via immune interferon and its effect on antigen presentation. J Immunol 134:3785–3793, 1985 Fierz W, Endler B, Reske K, et al: Astrocytes as antigen-presenting cells. 1. Induction of la antigen expression on astrocytes by T cells via immune interferon and its effect on antigen presentation. J Immunol 134:3785–3793, 1985
Fontana A, , Fierz W, & Wekerle H: Astrocytes present myelin basic protein to encephalitogenic T-cell lines. Nature 307:273–276, 1984 (Letter) Fontana A, Fierz W, Wekerle H: Astrocytes present myelin basic protein to encephalitogenic T-cell lines. Nature 307:273–276, 1984 (Letter)
Fontana A, , Kristensen F, & Dubs R, et al: Production of prostaglandin E and an interleukin-1 like factor by cultured astrocytes and C6 glioma cells. J Immunol 129:2413–2419, 1982 Fontana A, Kristensen F, Dubs R, et al: Production of prostaglandin E and an interleukin-1 like factor by cultured astrocytes and C6 glioma cells. J Immunol 129:2413–2419, 1982
Frank E, , Pulver M, & de Tribolet N: Expression of class II major histocompatibility antigens on reactive astrocytes and endothelial cells within the gliosis surrounding metastases and abscesses. J Neuroimmunol 12:29–36, 1986 Frank E, Pulver M, de Tribolet N: Expression of class II major histocompatibility antigens on reactive astrocytes and endothelial cells within the gliosis surrounding metastases and abscesses. J Neuroimmunol 12:29–36, 1986
Frei K, , Malipiero UV, & Leist TP, et al: On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases. Eur J Immunol 19:689–694, 1989 Frei K, Malipiero UV, Leist TP, et al: On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases. Eur J Immunol 19:689–694, 1989
Giulian D, & Lachman LB: Interleukin-1 stimulation of astroglial proliferation after brain injury. Science 228:497–499, 1985 Giulian D, Lachman LB: Interleukin-1 stimulation of astroglial proliferation after brain injury. Science 228:497–499, 1985
Giulian D, , Woodward J, & Young DG, et al: Interleukin-1 injected into mammalian brain stimulates astrogliosis and neovascularization. J Neurosci 8:2485–2490, 1988 Giulian D, Woodward J, Young DG, et al: Interleukin-1 injected into mammalian brain stimulates astrogliosis and neovascularization. J Neurosci 8:2485–2490, 1988
Hartung HP, , Schäfer B, & Heininger K, et al: Recombinant interleukin-1β stimulates eicosanoid production in rat primary culture astrocytes. Brain Res 489:113–119, 1989 Hartung HP, Schäfer B, Heininger K, et al: Recombinant interleukin-1β stimulates eicosanoid production in rat primary culture astrocytes. Brain Res 489:113–119, 1989
Helseth E, , Torp S, & Dalen A, et al: Effects of interferon-gamma and tumor necrosis factor-alpha on clonogenic growth of cell lines and primary cultures from human gliomas and brain metastases. APMIS 97:569–574, 1989 Helseth E, Torp S, Dalen A, et al: Effects of interferon-gamma and tumor necrosis factor-alpha on clonogenic growth of cell lines and primary cultures from human gliomas and brain metastases. APMIS 97:569–574, 1989
Helseth E, , Unsgaard G, & Dalen A, et al: Effects of type beta transforming growth factor in combination with retinoic acid or tumor necrosis factor on proliferation of a human glioblastoma cell line and clonogenic cells from freshly resected human brain tumors. Cancer Immunol Immunother 26:273–279, 1988 Helseth E, Unsgaard G, Dalen A, et al: Effects of type beta transforming growth factor in combination with retinoic acid or tumor necrosis factor on proliferation of a human glioblastoma cell line and clonogenic cells from freshly resected human brain tumors. Cancer Immunol Immunother 26:273–279, 1988
Hofman FM, , von Hanwehr RI, & Dinarello CA, et al: Immunoregulatory molecules and IL 2 receptors identified in multiple sclerosis brain. J Immunol 136:3239–3245, 1986 Hofman FM, von Hanwehr RI, Dinarello CA, et al: Immunoregulatory molecules and IL 2 receptors identified in multiple sclerosis brain. J Immunol 136:3239–3245, 1986
Jagadha V, , Halliday WC, & Becker LE: Glial fibrillary acidic protein (GFAP) in oligodendrogliomas: a reflection of transient GFAP expression by immature oligodendroglia. Can J Neurol Sci 13:307–311, 1986 Jagadha V, Halliday WC, Becker LE: Glial fibrillary acidic protein (GFAP) in oligodendrogliomas: a reflection of transient GFAP expression by immature oligodendroglia. Can J Neurol Sci 13:307–311, 1986
Janzer RC, & Raff MC: Astrocytes induce blood-brain barrier properties in endothelial cells. Nature 325:253–257, 1987 (Letter) Janzer RC, Raff MC: Astrocytes induce blood-brain barrier properties in endothelial cells. Nature 325:253–257, 1987 (Letter)
Kelly J, , Whelan CA, & Weir DG, et al: Removal of endogenous peroxidase activity from cryostat sections for immunoperoxidase visualisation of monoclonal antibodies. J Immunol Methods 96:127–132, 1987 Kelly J, Whelan CA, Weir DG, et al: Removal of endogenous peroxidase activity from cryostat sections for immunoperoxidase visualisation of monoclonal antibodies. J Immunol Methods 96:127–132, 1987
Kuppner MC, , Hamou MF, & Sawamura Y, et al: Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor β2. J Neurosurg 71:211–217, 1989 Kuppner MC, Hamou MF, Sawamura Y, et al: Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor β2. J Neurosurg 71:211–217, 1989
Lachman LB, , Brown DC, & Dinarello CA: Growth-promoting effect of recombinant interleukin 1 and tumor necrosis factor for a human astrocytoma cell line. J Immunol 138:2913–2916, 1987 Lachman LB, Brown DC, Dinarello CA: Growth-promoting effect of recombinant interleukin 1 and tumor necrosis factor for a human astrocytoma cell line. J Immunol 138:2913–2916, 1987
Lampson LA, & Hickey WF: Monoclonal antibody analysis of MHC expression in human brain biopsies: tissue ranging from “histologically normal” to that showing different levels of glial tumor involvement. J Immunol 136:4054–4062, 1986 Lampson LA, Hickey WF: Monoclonal antibody analysis of MHC expression in human brain biopsies: tissue ranging from “histologically normal” to that showing different levels of glial tumor involvement. J Immunol 136:4054–4062, 1986
Malipiero UV, , Frei K, & Fontana A: Production of hemopoietic colony-stimulating factors by astrocytes. J Immunol 144:3816–3821, 1990 Malipiero UV, Frei K, Fontana A: Production of hemopoietic colony-stimulating factors by astrocytes. J Immunol 144:3816–3821, 1990
Martin S, , Maruta K, & Burkart V, et al: IL-1 and IFN-γ increase vascular permeability. Immunology 64:301–305, 1988 Martin S, Maruta K, Burkart V, et al: IL-1 and IFN-γ increase vascular permeability. Immunology 64:301–305, 1988
Massa PT, , Dörries R, & ter Meulen V: Viral particles induce la antigen expression on astrocytes. Nature 320:543–546, 1986 (Letter) Massa PT, Dörries R, ter Meulen V: Viral particles induce la antigen expression on astrocytes. Nature 320:543–546, 1986 (Letter)
Merchant RE, , Fontana A, & Nelson AT Jr, et al: Mitogen-activated lymphocytes of normals and glioma patients produce factors with anti-glioblastoma activity in vitro. J Neuroimmunol 11:1–14, 1986 Merchant RE, Fontana A, Nelson AT Jr, et al: Mitogen-activated lymphocytes of normals and glioma patients produce factors with anti-glioblastoma activity in vitro. J Neuroimmunol 11:1–14, 1986
Merchant RE, , Grant AJ, & Merchant LH, et al: Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2. Cancer 62:665–671, 1988 Merchant RE, Grant AJ, Merchant LH, et al: Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2. Cancer 62:665–671, 1988
Merchant RE, , Merchant LH, & Cook SHS, et al: Intrale-sional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor. Neurosurgery 23:725–732, 1988 Merchant RE, Merchant LH, Cook SHS, et al: Intrale-sional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor. Neurosurgery 23:725–732, 1988
Merrill JE: Effects of interleukin-1 and tumor necrosis factor alpha on astrocytes, microglia, oligodendrocytes, and glial precursors in vitro. Dev Neurosci 13:130–137, 1991 Merrill JE: Effects of interleukin-1 and tumor necrosis factor alpha on astrocytes, microglia, oligodendrocytes, and glial precursors in vitro. Dev Neurosci 13:130–137, 1991
Merrill JE, & Zimmerman RP: Natural and induced cytotoxicity of oligodendrocytes by microglia is inhibitable by TGF beta. Glia 4:327–331, 1991 Merrill JE, Zimmerman RP: Natural and induced cytotoxicity of oligodendrocytes by microglia is inhibitable by TGF beta. Glia 4:327–331, 1991
Miescher S, , Whiteside TL, & de Tribolet N, et al: In situ characterization, clonogenic potential, and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancers. J Neurosurg 68:438–448, 1988 Miescher S, Whiteside TL, de Tribolet N, et al: In situ characterization, clonogenic potential, and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancers. J Neurosurg 68:438–448, 1988
Nieto-Sampedro M, & Berman MA: Interleukin-1-like activity in rat brain: sources, targets, and effect on injury. J Neurosci Res 17:214–219, 1987 Nieto-Sampedro M, Berman MA: Interleukin-1-like activity in rat brain: sources, targets, and effect on injury. J Neurosci Res 17:214–219, 1987
Ridley A, & Cavanagh JB: Lymphocytic infiltration in gliomas: evidence of possible host resistance. Brain 94:117–124, 1971 Ridley A, Cavanagh JB: Lymphocytic infiltration in gliomas: evidence of possible host resistance. Brain 94:117–124, 1971
Samuels V, , Barrett JM, & Bockman S, et al: Immunocyto-chemical study of transforming growth factor expression in benign and malignant gliomas. Am J Pathol 134:895–902, 1989 Samuels V, Barrett JM, Bockman S, et al: Immunocyto-chemical study of transforming growth factor expression in benign and malignant gliomas. Am J Pathol 134:895–902, 1989
Sawada M, , Kondo N, & Suzumura A, et al: Production of tumor necrosis factor-alpha by microglia and astrocytes in culture. Brain Res 491:394–397, 1989 Sawada M, Kondo N, Suzumura A, et al: Production of tumor necrosis factor-alpha by microglia and astrocytes in culture. Brain Res 491:394–397, 1989
Sawamura Y, , Abe H, & Aida T, et al: Isolation and in vitro growth of glioma-infiltrating lymphocytes, and an analysis of their surface phenotypes. J Neurosurg 69:745–750, 1988 Sawamura Y, Abe H, Aida T, et al: Isolation and in vitro growth of glioma-infiltrating lymphocytes, and an analysis of their surface phenotypes. J Neurosurg 69:745–750, 1988
Sawamura Y, , Hosokawa M, & Kuppner MC, et al: Antitumor activity and surface phenotypes of human glioma-infiltrating lymphocytes after in vitro expansion in the presence of interleukin 2. Cancer Res 49:1843–1849, 1989 Sawamura Y, Hosokawa M, Kuppner MC, et al: Antitumor activity and surface phenotypes of human glioma-infiltrating lymphocytes after in vitro expansion in the presence of interleukin 2. Cancer Res 49:1843–1849, 1989
Selmaj KW, , Farooq M, & Norton WT, et al: Proliferation of astrocytes in vitro in response to cytokines: a primary role for tumor necrosis factor. J Immunol 144:129–135, 1990 Selmaj KW, Farooq M, Norton WT, et al: Proliferation of astrocytes in vitro in response to cytokines: a primary role for tumor necrosis factor. J Immunol 144:129–135, 1990
Siepl C, , Bodmer S, & Frei K, et al: The glioblastoma-derived T cell suppressor factor/transforming growth factor-β2 inhibits T cell growth without affecting the interaction of interleukin 2 with its receptor. Eur J Immunol 18:593–600, 1988 Siepl C, Bodmer S, Frei K, et al: The glioblastoma-derived T cell suppressor factor/transforming growth factor-β2 inhibits T cell growth without affecting the interaction of interleukin 2 with its receptor. Eur J Immunol 18:593–600, 1988
Sun D, & Wekerle H: Ia-restricted encephalitogenic T lymphocytes mediating EAE lyse autoantigen-presenting astrocytes. Nature 320:70–72, 1986 (Letter) Sun D, Wekerle H: Ia-restricted encephalitogenic T lymphocytes mediating EAE lyse autoantigen-presenting astrocytes. Nature 320:70–72, 1986 (Letter)
Tedeschi B, , Barrett JN, & Keane RW: Astrocytes produce interferon that enhances the expression of H-2 antigens on a subpopulation of brain cells. J Cell Biol 102:2244–2253, 1986 Tedeschi B, Barrett JN, Keane RW: Astrocytes produce interferon that enhances the expression of H-2 antigens on a subpopulation of brain cells. J Cell Biol 102:2244–2253, 1986
Tsunawaki S, , Sporn M, & Ding A, et al: Deactivation of macrophages by transforming growth factor-β. Nature 334:260–262, 1988 (Letter) Tsunawaki S, Sporn M, Ding A, et al: Deactivation of macrophages by transforming growth factor-β. Nature 334:260–262, 1988 (Letter)
Vita JR, , Edwalds GM, & Gorey T, et al: Enhanced in vitro growth suppression of human glioblastoma cultures treated with the combination of recombinant fibroblast and immune interferons. Anticancer Res 8:297–302, 1988 Vita JR, Edwalds GM, Gorey T, et al: Enhanced in vitro growth suppression of human glioblastoma cultures treated with the combination of recombinant fibroblast and immune interferons. Anticancer Res 8:297–302, 1988
von Hanwehr RI, , Hofman FM, & Taylor CR, et al: Mononuclear lymphoid populations infiltrating the microenvi-ronment of primary CNS tumors. Characterization of cell subsets with monoclonal antibodies. J Neurosurg 60:1138–1147, 1984 von Hanwehr RI, Hofman FM, Taylor CR, et al: Mononuclear lymphoid populations infiltrating the microenvi-ronment of primary CNS tumors. Characterization of cell subsets with monoclonal antibodies. J Neurosurg 60:1138–1147, 1984
Yoshida S, , Tanaka R, & Ono M, et al: Analysis of mixed lymphocyte-tumor culture in patients with malignant brain tumor. J Neurosurg 71:398–402, 1989 Yoshida S, Tanaka R, Ono M, et al: Analysis of mixed lymphocyte-tumor culture in patients with malignant brain tumor. J Neurosurg 71:398–402, 1989
| All Time | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 657 | 109 | 11 |
| Full Text Views | 228 | 7 | 0 |
| PDF Downloads | 122 | 5 | 0 |
| EPUB Downloads | 0 | 0 | 0 |